{"id":924931,"date":"2026-01-07T09:32:33","date_gmt":"2026-01-07T14:32:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/study-showed-minimed-780g-system-achieved-ada-recommended-time-in-range-goals-even-on-days-users-forgot-to-bolus\/"},"modified":"2026-01-07T09:32:33","modified_gmt":"2026-01-07T14:32:33","slug":"study-showed-minimed-780g-system-achieved-ada-recommended-time-in-range-goals-even-on-days-users-forgot-to-bolus","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/study-showed-minimed-780g-system-achieved-ada-recommended-time-in-range-goals-even-on-days-users-forgot-to-bolus\/","title":{"rendered":"Study showed MiniMed\u2122 780G system achieved ADA-recommended time-in-range goals even on days users forgot to bolus"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n GALWAY, Ireland<\/span>, Jan. 7, 2026<\/span> \/PRNewswire\/ — A new real-world retrospective analysis published in Diabetes Care<\/i><\/a>\u00a0showed that users of the MiniMed\u2122 780G system achieved American Diabetes Association (ADA) recommended goals for time-in-range (TIR)\u2014 even on days when mealtime boluses\u00a0were missed.\u00a0CareLink\u2122 data showed that the studied user population achieved 76.3% TIR on missed bolus days when using SmartGuard\u2122 technology with recommended optimal settings (100 mg\/dL glucose target; two-hour active insulin time). The study investigated off-label user behavior as the system labeling requires users to announce meals when using SmartGuard\u2122 technology. Deliberately not bolusing is an unapproved use of the device and is not recommended. While meal announcement is required, this study highlights the importance of optimized settings, especially when some users occasionally missed\u00a0boluses.<\/p>\n

\n Mealtime burden
<\/b>Mealtimes are one of the biggest challenges for people living with type 1 diabetes and frequently linked to diabetes distress.1,2<\/sup> The constant need for decision-making and mental load around calculating carbohydrates and insulin requirements at mealtimes contributes to the overall burden of the condition. Missed boluses can significantly impact diabetes management and glycemic outcomes. A 2024 study published in Diabetes Technology & Therapeutics<\/i> found that children and adolescents using AID systems missed an average of 2.2 boluses per day, with each additional missed bolus reducing TIR by nearly 10%.3<\/sup><\/p>\n

“While labeling requires meal bolusing for all automated insulin delivery systems, including the MiniMed\u2122 780G system, missed boluses are a reality in real-world use,” said\u00a0Jennifer McVean, MD, Senior Medical Affairs Director, Medtronic Diabetes, and lead investigator of the study. “Using real-world CareLink\u2122 data, this analysis showed that when using recommended optimal settings, 71.2% of MiniMed\u2122 780G system users studies achieved ADA-recommended TIR goals on days when meal boluses were missed.”<\/p>\n

While announcing meals is required per the labeling of the MiniMed\u2122 780G system, the algorithm adjusts the delivery of insulin every five minutes based on sensor readings to auto-correct\u2020<\/sup> glucose levels\u2014providing support when boluses are occasionally missed or carbohydrates are underestimated.\u00a0The MiniMed\u2122 780G system is not approved for no bolusing for meals.\u00a0<\/p>\n

\n Study Design & Key Findings
<\/b>The study retrospectively analyzed real-world global CareLink user\u00a0data (N=369,467) of those using the MiniMed\u2122 780G insulin pump with a compatible Medtronic sensor\u2021<\/sup> who experienced at least 10 days without bolusing (N=54,553) between January 2, 2020 to March 31, 2025. \u00a0<\/p>\n

The analysis compared glycemic outcomes on missed bolus days with (N=12,723) and without (N=41,830) use of the recommended optimal settings.\u00a0Those using the recommended optimal settings achieved significantly better outcomes than those using other settings in all age groups, including both\u00a0type 1diabetes and type 2 diabetes\u00a0populations:<\/p>\n